A novel chimeric recombinant FliC-Pgp3 vaccine promotes immunoprotection against Chlamydia muridarum infection in mice

Zhao, Lanhua; Wang, Xinglv; Li, Zhongyu

doi:10.1016/j.ijbiomac.2023.128723

International Journal of Biological Macromolecules

2024

DOI: 10.1016/j.ijbiomac.2023.128723

|View full text |Cite

A novel chimeric recombinant FliC-Pgp3 vaccine promotes immunoprotection against Chlamydia muridarum infection in mice

Lanhua Zhao,

Xinglv Wang,

Zhongyu Li

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article2

Relationship

Self Cite0

Independent2

Authors

Journals

Cited by 2 publications

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Bacterial ghosts engineered with lipidated antigens as an adjuvant-free vaccine for Chlamydia abortus

Zhang,

Li,

et al. 2024

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Bacterial ghosts engineered with lipidated antigens as an adjuvant-free vaccine for Chlamydia abortus

Zhang,

Li,

et al. 2024

International Journal of Pharmaceutics

View full text Add to dashboard Cite

Progress towards effective vaccines for Chlamydia trachomatis

Collar,

Frietze

2024

Current Opinion in Infectious Diseases

View full text Add to dashboard Cite

Purpose of review Effective vaccines to prevent sexually transmitted Chlamydia trachomatis (Ct) infection have eluded researchers for decades. However, recent studies of a promising vaccine in human trials, and emerging understanding of the complexity of the natural immune response to infection have provided hope for the eventual approval of a vaccine. This review highlights recent progress toward developing effective vaccines for Ct. Recent findings In 2019, the first-in-human Ct vaccine, CTH522, Phase I/IIB trial was reported. Recent studies of this vaccine and its derivatives have further established CTH522 as the lead vaccine against sexually transmitted Ct. A variety of vaccines have entered the preclinical development pipeline, with researchers reporting efforts to target non-MOMP antigens, include novel adjuvants in vaccine formulations, and use alternative routes of administration to increase efficacy. Summary While the approval of a vaccine for Ct is closer than ever, the need for careful consideration of future implementation is especially important for the successful clinical translation of Ct vaccines into humans.

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

A novel chimeric recombinant FliC-Pgp3 vaccine promotes immunoprotection against Chlamydia muridarum infection in mice

Cited by 2 publications

References 48 publications

Bacterial ghosts engineered with lipidated antigens as an adjuvant-free vaccine for Chlamydia abortus

Bacterial ghosts engineered with lipidated antigens as an adjuvant-free vaccine for Chlamydia abortus

Progress towards effective vaccines for Chlamydia trachomatis

Contact Info

Product

Resources

About